Claims for Patent: 6,784,197

Summary for Patent: 6,784,197

Title:	2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
Abstract:	The invention concerns 2-oxo-1-pyrrolidine derivatives of formula (I) wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy.
Inventor(s):	Edmond Differding, Benoît Kenda, Bénédicte Lallemand, Alain Matagne, Philippe Michel, Patrick Pasau, Patrice Talaga
Assignee:	UCB Biopharma SRL
Application Number:	US10/204,266
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,784,197
Patent Claims:	1. A compound having the formula I or a pharmaceutically acceptable salt thereof, wherein X is —CA1NR5R6 or —CA1—R8; A1 and A2 are independently oxygen, sulfur or —NR9; R1 is hydrogen, alkyl, aryl or —CH2—R1a wherein R1a is aryl, halogen, hydroxy, amino, nitro or cyano; R3 is hydrogen, halogen, thiol, nitro, nitrooxy, cyano, azido, carboxy, amido, sulfonic acid, sulfonamide, alkyl, alkenyl, alkenyl, ester, ether, aryl, tetrazolyl, thiazolyl, thienyl, furyl, pyrrolyl, pyridinyl, alkynyloxy, acyloxy, oxyester, oxyamido, alkylsulfonyloxy, alkylsulfinyloxy, arylsulfonyloxy, arylsulfinyloxy, aryloxy, aralkoxy, alkythio, alkenylthio, alkynylthio, arylthio, formyl, acetyl, propionyl, isobutyryl, valeryl, lauroyl, heptanedioyl, cyclohexanecarbonyl, crotonoyl, furmaroyl, arcyrloyl, benzoyl, naphthoyl, 4-carboxybutanoyl, oxalyl, ethoxalyl, cysteinyl, oxamoyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, alkylsulfinyl, alkenylsulfinyl, alkynylsufinyl or arylsulfinyl, R3a is hydrogen, halogen, alkyl, alkenyl, alkynyl or aryl; R5, R6 and R9 are the same or different and each is independently hydrogen, hydroxy, alkyl, aryl, alkoxy, alkenyloxy, alkynyloxy, acyloxy, oxyester, oxyamido, alkylsufonyloxy, alkylsulfinyloxy, arylsulfonyloxy, arylsufinyloxy, aryloxy or arylalkoxy and R8 is hydrogen, hydroxy, thiol, halogen, alkyl, aryl, alkylthio, alkenylthio, alkynylthio or with the provisos that at least one of as R3 and R3a is other than hydrogen; and that when the compound is a mixture of all possible isomers , X is —CONR5R6, A2 is oxygen and R1is hydrogen, methyl, ethyl or propyl then substitution on the pyrrolidine ring is other than mono-, di-methyl or mono-ethyl; and that when R1 and R3a are both hydrogen, A2 is oxygen and X is —CONR5R6 then R3 is different from carboxy, ester, amido, substituted oxo-pyrrolidine, alkynyloxy, acyloxy, oxyester, oxyarmido, alkylsulfonyloxy, alkylsulfinyloxy, arylsulfonyloxy, arylsulfinyloxy, aryloxy, aralkoxy, methyl, naphthyl, phenyl optionally substituted by oxy derivatives or in the para position by an halogen atom. 2. The compound according to claim 1 wherein X represents a substituent group selected from, a) —CONR5R6; b) —CONR5R6, wherein R5 and R4 are hydrogen, C1-4-alkyl, phenyl or alkylphenyl; c) —CONR5R6, wherein R5 and R6 are independently hydrogen, methyl, ethyl, propyl, isopropyl, butyl, iso or ter-butyl, 2,2-dimethylpropyl; d) —CONR5R6, wherein R5 and R6 are independently hydrogen or methyl; e) —CONR5R6, wherein at least one of R5 and R6 is hydrogen or both are hydrogen; or f) —CONH2. 3. The compound according to claim 1 wherein R1 represents a substituent group selected from, a) hydrogen, alkyl or aryl; b) hydrogen, C1-12 alkyl or aryl; c) hydrogen, lower alkyl or phenyl; d) methyl, ethyl, propyl, isopropyl, butyl, iso- or ter-butyl, 2,2,2-trimethylethyl, each optionally attached via a methylene bridge or the same substituted by at least one halogen atom; or e) ethyl. 4. The compound according to claim 1 wherein R3a is a substituent group selected from, a) hydrogen, alkyl, aryl or aralkyl; b) hydrogen, methyl, ethyl, phenyl or benzyl; c) hydrogen, halogen or methyl, ethyl, propyl, isopropyl, butyl, iso or ter-butyl, 2,2,2-trimethylethyl or the same substituted by at least one halogen atom. 5. The compound according to claim 4, wherein R3a represents a substituent group selected from, a) hydrogen or alkyl; b) hydrogen or lower alkyl; or c) hydrogen. 6. The compound according to claim 1 wherein R3 is a substituent group selected from, a) hydrogen, C1-12-alkyl each optionally substituted by one or more substituents selected from hydroxy, halogen, cyano, thiocyanato or alkoxy C2-6-alkenyl or -alkynyl, each optionally substituted by one or more halogens; azido; cyano; amido; carboxy; tetrazolyl, pyridyl, 1-oxidopyridyl, furyl, pyrrolyl, thiazolyl or thienyl, thiazolyl or thienyl each optionally substituted by one or more substituents selected from halogen, C1-6-alkyl and phenyl and attached to the ring either directly or via a C1-4-alkylene bridge; naphthyl; or phenyl, phenylalkyl or phenylalkenyl each optionally substituted by one or more substituents selected from halogen, C1-6-alkyl, C1-6 haloalkyl, C1-6-alkoxy, C1-6-alkylthio, amino, azido, phenyl and nitro; b) as a) except that any alkyl is C1-6-alkyl and any C1-4 alkylene bridge is methylene; c) C1-6-alkyl optionally substituted by one or more substituents selected from halogen, thiocyanato, azido, alkoxy, alkylthio, phenylsulfonyl; nitrooxy; C2-3-alkenyl or -alkynyl each optionally substituted by one or more halogens or by acetyl; tetrazolyl, pyridyl, furyl, pyrrolyl, thiazolyl or thienyl; or phenyl or phenylalkyl each optionally substituted by one or more substituents selected from halogen, C1-6-alkyl, C1-6 haloalkyl, C1-6-alkoxy, amino, azido, phenyl and nitro; d) hydrogen, halogen or methyl, ethyl, propyl, isopropyl, butyl, iso or ter-butyl, 2,2,2-trimethylethyl or the same substituted by at least one halogen atom; e) C1-4-alkyl optionally substituted by one or more substituents selected from halogen, thiocyanato or azido; C2-5-alkenyl or -alkynyl, each optionally substituted by one or more halogens; thienyl; or phenyl optionally substituted by one or more substituents selected from halogen, C1-6-alkyl, C1-6 haloalkyl or azido; or f) C1-6-alkyl and C2-6-haloalkenyl. 7. The compound according to claim 1 wherein R1 is a substituent group selected from, a) hydrogen, methyl, ethyl, propyl, isopropyl, butyl, iso or ter-butyl, 2,2,2-trimethylethyl, phenyl, benzyl or the same substituted by at least one halogen atom; or b) hydrogen or methyl. 8. The compound according to claim 1, wherein, A2 is oxygen; X is —CONR5R6 or —CO—R8; R1 is hydrogen or alkyl, aryl, halogen, hydroxy, amino, nitro, cyano; R3 is hydrogen or halogen, nitro, cyano, acyl, acyloxy, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, carboxy, ester, ether, amido, sulfonic acid, sulfonamide, alkoxycarbonyl, alkylthio, alkenylthio, alkynylthio, arylthio, alkyl, oxyester, oxyamido, aryl, alkynyloxy, acyloxy, oxyester, oxyamido, alkylsulfonyloxy, alkylsulfinyloxy, arylsulfonyloxy, arylsulfinyloxy, aryloxy, aralkoxy, tetrazolyl, thiazolyl, thienyl, furyl, pyrrolyl, pyridinyl, vinyl and R3 may additionally represent C2-5 alkenyl, C2-5 alkyrnyl or azido each optionally substituted by one or more halogen, cyano, thiocyano, azido, cyclopropyl, acyl and/or phenyl; or phenylsulfonyloxy whereby any phenyl moiety may be substituted by one or more halogen, alkyl, haloalkyl, alkoxy, nitro, amino, and/or phenyl; R3a is hydrogen; R5 and R6 are the same or different and each is independently hydrogen, hydroxy, alkyl, aryl alkoxyl, alkenyloxy, alkynyloxy, acyloxy, oxyester, oxyamido, alkylfonyloxy, alkylsulfinyloxy, arylsulfonyloxy, arylsulfinyloxy, aryloxy or arylalkoxy; and R8 is hydrogen, hydroxy, thiol, halogen, alkyl, aryl, alkylthio, alkylthio, alkenylthio, alkynylthio or arylthio. 9. The compound according to claim 8, wherein R1 is methyl, ethyl, propyl, isopropyl, butyl or isobutyl; R3 is C1-5 alkyl, C2-5 alkenyl, C2-C5 alkynyl, cyclopropyl, azido, each optionally substituted by one or more halogen, cyano, thiocyano, azido, alkylthio, cyclopropyl, acyl and/or phenyl; phenyl; phenylsulfonyl; phenylsulfonyloxy, tetrazole, thiazole, thienyl, furyl, pyrrole, pyridine, whereby any phenyl moiety may be substituted by one or more halogen, alkyl, haloalkyl, alkoxy, nitro, amino, and/or phenyl; X is —COOH or —CONH2. 10. The compound according to claim 9, wherein R1 is methyl, ethyl or n-propyl; and X is —CONH2. 11. The compound according to claim 1, wherein X is —CA1NH2, —CA1NHCH3 or —CA1N (CH3)2; R1 is alkyl or phenyl; R3 is alkyl, alkenyl, alkynyl, cyano, isothiocyanato, ether, carboxyl, amido, aryl tetrazolyl, thiazolyl, thienyl, furyl, pyrrolyl, pyridinyl; or R3 is C2R10 wherein R10 hydrogen, cycloalkyl, oxyester, oxyalkylsulfonyl, oxyarylsufonyl, aminoalkylsulfonyl, aminoarylsulfonyl, nitrooxy, cyano, isothiocyanato, azido, alkylthio, arylthio, alkylsulfinyl, alkylsulfonyl, tetrazolyl, thiazolyl, thienyl, furyl, pyrrolyl, pyridinyl, aryloxy, alkoxy or trifluoroethyl; R3a is hydrogen, alkyl or aryl; or R3 and R3a form a cycloalkyl. 12. The compound according to claim 1, wherein R1 is alkyl; R3a is hydrogen; R3 is hydrogen; C1-12-alkyl optionally substituted by one or more substituents selected from hydroxy, halogen, cyano, thiocyanato or alkoxy; C2-6-alkenyl or -alkynyl, each optionally substituted by one or more halogens; azido; cyano; amido; carboxy; tetrazolyl, pyridyl, 1-oxidopyridyl, furyl, pyrrolyl, thiazolyl or thienyl each optionally substituted by one or more substituents selected from halogen, C1-6-alkyl and phenyl and attached to the ring either directly or via a C1-4-alkylene bridge; naphthyl; or phenyl, phenylalkyl or phenylalkenyl each optionally substituted by one or more substituents selected from halogen, C1-6-alkyl, C1-6 haloalkyl, C1-6-alkoxy, C1-6-alkylthio, amino, azido, phenyl and nitro. 13. The compound according to claim 12, wherein, R1 is a substituent group selected from a) C1-12-alkyl; b) C1-6-alkyl; or c) ethyl; and any C1-4-alkylene bridge present is methylene. 14. The compound according to claim 1, which is in racemic form and wherein when X is —CONR5R6 and R1 is hydrogen, methyl, ethyl or propyl, then substitution on the pyrrolidine ring is other than mono-, di-methyl or mono-ethyl. 15. The compound according to claim 1, which is in racemic form and wherein when X is —CONR5R6 and R1 is hydrogen or C1-6-alkyl, C2-6-alkenyl or -alkynyl or cycloalkyl, each unsubstituted, then substitution in the ring is other than by alkyl, alkenyl or alkynyl, each unsubstituted. 16. The compound according to claim 1, wherein, X is —CA1NH2; R1 is hydrogen; R3 is azidomethyl, iodomethyl, C2-6-alkyl optionally substituted by 1 to 5 halogen atoms, vinyl optionally subsituted by one or two methyls, and/or 1 to 3 halogen atoms, acetylene optionally substituted by C1-4-alkyl, phenyl or halogen and R3a is hydrogen or halogen; as their racemates or in enantiomerically enriched form. 17. The compound according to claim 1, wherein X is —CA1NH2; R1 is H; R3 is C1-6-alkyl, C2-6-alkenyl or C2-6-alkynyl optionally substituted by azido, oxynitro, 1 to 6 halogen atoms; and R3a is hydrogen or halogen; as their racemates or in enantiomerically enriched form. 18. The compound according to claim 1, wherein A2 is oxygen; R1 is ethyl; X is —CONH2; R3 is n-propyl or 2,2-difluorovinyl; and R3a is hydrogen. 19. The compound according to claim 1 as a pure enantiomer. 20. The compound according to claim 1, which, when the carbon atom to which R1 is attached is asymmetric, is in the “S”-configuration. 21. A compound selected from (2S)-2-[4-(bromomethyl)-2-oxo-1-pyrrolidinyl]butanamide; (2S)-2-[(4R)-4-(iodomethyl)-2-oxopyrrolidinyl]butanamide; (2S)-2-(2-oxo-4-phenyl-1-pyrrolidinyl)butanamide; (2S)-2-[4-(iodomethyl)-2-oxo-1-pyrrolidinyl]butanamide; (2S)-2-[4-(chloromethyl)-2-oxo-1-pyrrolidinyl]butanamide; {1-[(1S)-1-(aminocarbonyl)propyl]-5-oxo-3-pyrrolidinyl}methyl 4-methylbenzenesulfonate; (2S)-2-[(4R)-4-(azidomethyl)-2-oxopyrrolidinyl]butanamide; 2-[4-(2,2-dibromovinyl)-2-oxo-1-pyrrolidinyl]butanamide; {1-[(1S)-1-(aminocarbonyl)propyl]-5-oxo-3-pyrrolidinyl}methyl nitrate; (2S)-2-[2-oxo-4-(1H-tetraazol-1-ylmethyl)-1-pyrrolidinyl]butanamide; 2-(2-oxo-4-vinyl-1-pyrrolidinyl)butanamide; 2-{2-oxo-4-[(phenylsulfonyl)methyl]-1-pyrrolidinyl}butanamide; (2S)-2-[(4R)-4-(2,2-dibromovinyl)-2-oxopyrrolidinyl]butanamide; (2S)-2-[(4S)-4-(2,2-dibromovinyl)-2-oxopyrrolidinyl]butananmide; (2S)-2-[4-(isothiocyanatomethyl)-2-oxo-1-pyrrolidinyl]butanamide; 2-[2-oxo-4-(1,3-thiazol-2-yl)-1-pyrrolidinyl]butanamide; (2S)-2-[2-oxo-4-(2-thienyl)-1-pyrrolidinyl]butanamide; (2S)-2-[4-(2-methoxyphenyl)-2-oxo-1-pyrrolidinyl]butanamide; (2S)-2-[4-(3-methoxyphenyl)-2-oxo-1-pyrrolidinyl]butanamide; (2S)-2-[4-(4-azidophenyl)-2-oxo-1-pyrrolidinyl]butanamide; (2S)-2-[2-oxo-4-(3-thienyl)-1-pyrrolidinyl]butanamide; (2S)-2-[4-(3-azidophenyl)-2-oxo-1-pyrrolidinyl]butanamide; (2S)-2-[2-oxo-4-(3-thienyl)-1-pyrrolidinyl]butanamide; (2S)-2-[(4S)-2-oxo-4-vinylpyrrolidinyl]butanamide; (2S)-2-[(4R)-2-oxo-4-vinylpyrrolidinyl]butanamide; 2-[4-(2-bromophenyl)-2-oxo-1-pyrrolidinyl]butanamide; 2-[2-oxo-4-(3-pyridinyl)-1-pyrrolidinyl]butanamide; (2S)-2-(4-[1,1′-biphenyl]-4-yl-2-oxo-1-pyrrolidinyl)butanamide; (2S)-2-{4-[(methylsulfanyl)methyl]-2-oxo-1-pyrrolidinyl}butanamide; 2-[4-(iodomethyl)-2-oxo-1-pyrrolidinyl]butanamide; (2S)-2-[(4R)-4-(iodomethyl)-2-oxo-1-pyrrolidinyl]pentanamide; (2S)-2-[(4R)-4-(iodomethyl)-2-oxopyrrolidinyl]propanamide; 2-(2-oxo-4-propyl-1-pyrrolidinyl)propanamide; 2-(2-oxo-4-propyl-1-pyrrolidinyl)butanamide; 2-(2-oxo-4-pentyl-1-pyrrolidinyl)butanamide; (2S)-2-[(4R)-4-(iodomethyl)-2-oxopyrrolidinyl]-N-methylbutanamide; (2S)-2-(4-neopentyl-2-oxo-1-pyrrolidinyl)butanamide; (2S)-2-(4-ethyl-2-oxo-1-pyrrolidinyl)butanamide; 2-[4-(2,2-difluorovinyl)-2-oxo-1-pyrrolidinyl)butanamide; 2-[4-(2,2-difluoroethyl)-2-oxo-1-pyrrolidinyl]butanamide; (2S)-2-[(4S)-2-oxo-4-propylpyrrolidinyl]butanamide; (2S)-2-[(4R)-2-oxo-4-propylpyrrolidinyl]butanamide; 2-{4-[(Z)-2-fluoroethenyl]-2-oxo-1-pyrrolidinyl}butanamide; 2-[4-(2-methyl-1-propenyl)-2-oxo-1-pyrrolidinyl]butanamide; 2-(4-butyl-2-oxo-1-pyrrolidinyl)butanamide; 2-[4-(cyclopropylmethyl)-2-oxo-1-pyrrolidinyl]butanamide; 2-(4-isobutyl-2-oxo-1-pyrrolidinyl)butanamide; 2-[4-(4-chlorophenyl)-2-oxo-1-pyrrolidinyl]butanamide; 2-(4-(3-chlorophenyl)-2-oxo-1-pyrrolidinyl]butanamide; 2-{2-oxo-4-[2-(trifluoromethyl)phenyl]-1-pyrrolidinyl}butanamide; 2-[4-(2-fluorophenyl)-2-oxo-1-pyrrolidinyl]butanamide; 2-[4-(3-methylphenyl)-2-oxo-1-pyrrolidinyl]butanamide; (2S)-2-[2-oxo-4-(2-phenylethyl)-1-pyrrolidinyl]butanamide, (2S)-2-[4-(3-bromophenyl)-2-oxo-1-pyrrolidinyl]butanamide; 2-{4-[3,5-bis(trifluoromethyl)phenyl]-2-oxo-1-pyrrolidinyl}butanamide; 2-[4-(3,4-dichlorophenyl)-2-oxo-1-pyrrolidinyl]butanamide; 2-[4-(2,4-dichlorophenyl)-2-oxo-1-pyrrolidinyl]butanamide; 2-[4-(2-furyl)-2-oxo-1-pyrrolidinyl]butanamide; (2S)-2-[2-oxo-4-(3-phenylpropyl)-1-pyrrolidinyl]butanamide; (2S)-2-[4-(3,5-dibromophenyl)-2-oxo-1-pyrrolidinyl]butanamide; 2-[4-(3,4-dichlorophenyl)-2-oxo-1-pyrrolidinyl]butanamide; 2-(2-oxo-4-propyl-1-pyrrolidinyl)butanamide; 2-[4-(3-chlorophenyl)-2-oxo-1pyrrolidinyl]butanamide; 2-(4-ethynyl-2-oxo-1-pyrrolidinyl) butanamide; 2-[4-(2-fluorophenyl)-2-oxo-1-pyrrolidinyl]butanamide; 2-[4-(2-fluorophenyl)-2-oxo-1-pyrrolidinyl]butanamide; (2S)-2-[4-(cyclopropylmethyl)-2-oxo-1-pyrrolidinyl]butanamide; (2S)-2-[(4S)-4-(2,2-difluorovinyl)-2-oxopyrrolidinyl]butanamide; (2S)-2-[2-oxo-4-(3,3,3-trifluoropropyl)-1-pyrrolidinyl]butanamide; 2-[4-(3-methylphenyl)-2-oxo-1-pyrrolidinyl]butanamide; (2S)-2-[4-(cyclopropylmethyl)-2-oxo-1-pyrrolidinyl]butanamide; (2S)-2-[(4R)-4-(2,2-difluorovinyl)-2-oxopyrrolidinyl]butanamide; (2S)-2-[2-oxo-4-(1H-pyrrol-1-yl)-1-pyrrolidinyl]butanamide; (2S)-2-(4-allyl-2-oxo-1-pyrrolidinyl)butanamide; (2S)-2-(4-(2-iodopropyl)-2-oxo-1-pyrrolidinyl]butanamide; (2S)-2-(4-allyl-2-oxo-1-pyrrolidinyl)butanamide; (2S)-2-[2-oxo-4-(2-oxopropyl)-1-pyrrolidinyl]butanamide; (2S)-2-[4-(2-bromo-1H-pyrrol-1-yl)-2-oxo-1-pyrrolidinyl]butanamide; (2S)-2-(4-methyl-2-oxo-4-propyl-1-pyrrolidinyl)butanamide; (2R)-2-[4-(2,2-dichlorovinyl)-2-oxo-1-pyrrolidinyl]butanamide, 2-[4-(bromoethynyl)-2-oxo-1-pyrrolidinyl]butanamide; 2-[(4S)-4-(2,2-difluoropropyl)-2-oxopyrrolidinyl]butanamide; (2S)-2-[4-(bromoethynyl)-2-oxo-1-pyrrolidinyl]butanamide; 2(2-oxo-4-propyl-1-pyrrolidinyl)pentanamide; 3-cyclopropyl-2-(2-oxo-4-propyl-1-pyrrolidinyl)propanamide; 2-(2-oxo-4-propyl-1-pyrrolidinyl)-3-(1,3-thiazol-4-yl)propanamide; 2-(2-oxo-4-propyl-1-pyrrolidinyl)-4-pentanamide; ethyl 3-({[(1S)-1-(aminocarbonyl)propyl]amino}methyl)hexanoate hydrochloride; 2-(1-adamantyl)ethyl 3-({[(1S)1-(aminocarbonyl)propyl]amino}methyl)hexanoate hydrochloride; butyl 3-({[(1S)-1-(aminocarbonyl)propyl]amino}methyl)hexanoate hydrochloride and isopropyl 3-({[(1S)-1-(aminocarbonyl)propyl]amino}methyl)hexanoate hydrochloride, including all isomeric forms and mixtures thereof or a pharmaceutically acceptable salt thereof. 22. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 in combination with a pharmaceutically acceptable diluent or carrier. 23. A method for treating epilepsy, epileptogenesis, seizure disorders, convulsions, bipolar disorders, mania, depression, anxiety, migraine, trigeminal and other neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythmia, myotonia, cocaine abuse, stroke, myoclonus, neonatal cerebral hemorrhage, amyotrophic lateral sclerosis, spasticity, Parkinson's disease, bronchial asthma, asthmatic status and allergic bronchitis, asthmatic syndrome, bronchial hyperreactivity and bronchospastic syndromes as well as allergic and vasomotor rhinitis and rhinoconjunctivitis, in a mammal in need of such treatment, comprising administering a therapeutic dose of at least one compound according claim 1. 24. A method for treating epilepsy, epileptogenesis, seizure disorders, convulsions, bipolar disorders, mania, depression, anxiety, migraine, trigeminal and other neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythmia, myotonia, cocaine abuse, stroke, myoclonus, neonatal cerebral hemorrhage, amyotrophic lateral sclerosis, spasticity, Parkinson's disease, bronchial asthma, asthmatic status and allergic bronchitis, asthmatic syndrome, bronchial hyperreactivity and bronchospastic syndromes as well as allergic and vasomotor rhinitis and rhinoconjunctivitis, in a mammal in need of such treatment, comprising administering a therapeutic dose of at least one compound of formula I as illustrated in claim 1 or a pharmaceutically acceptable salt thereof, wherein the individual substituents are as defined in claim 1 with the provisos that at least one of as R3and R3a is other than hydrogen; and that when the compound is a mixture of all possible isomers, X is —CONR5R6, A2 is oxygen and R1 is hydrogen, methyl, ethyl or propyl then substitution on the pyrollidine ring is other than mono-, di-methyl or mono-ethyl. 25. A method for treating epilepsy, epileptogenesis, seizure disorders, convulsions, bipolar disorders, mania, depression, anxiety, migraine, trigeminal and other neuralgia, chronic pain, neuropathic pain, cerebral isehemia, cardiac arrhythmia, myotonia, cocaine abuse, stroke, myoclonus, neonatal cerebral haemorrhage, amyotrophic lateral sclerosis, spasticity, Parkinson's disease bronchial asthma, asthmatic status and allergic bronchitis, asthmatic syndrome, bronchial hyperreactivity and bronchospastic syndromes as well as allergic and vasomotor rhinitis and rhinoconjunctivitis, in a mammal in need of such treatment, comprising administering a therapeutic dose of at least one compound according to claim 21. 26. The method according to claim 24, wherein the condition to be treated is epilepsy, neuropathic pain, bipolar disorder or migraine. 27. The method according to claim 25, wherein the condition to be treated is epilepsy, neuropathic pain, bipolar disorder or migraine. 28. The compound according to claim 6, wherein the C1-4-alkylene bridge is methylene. 29. The compound according to claim 9, wherein R3 is methyl, ethyl, propyl, isopropyl, butyl or isobutyl. 30. The compound according to claim 16 wherein R3a is fluorine and the compound is the pure enantiomer. 31. The compound according to claim 17 wherein R3a is fluorine and the compound is the pure enantiomer.